(February 19, 2021, 1:02 PM EST) -- ALEXANDRIA, Va. — In a Feb. 17 petition for inter partes review (IPR), a pharmaceutical company maintains that the Patent Trial and Appeal Board should cancel 19 claims of a patented myopia treatment featuring increased pH stability via substitution of deuterium oxide (D2O) for regular water (H2O)....